Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis (original) (raw)
References
Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int. 2007;1:316–325 ArticlePubMedPubMed Central Google Scholar
Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160274 ArticlePubMed Google Scholar
Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7:796–829 Article Google Scholar
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Korean Liver Cancer Stud Group 2022;0.
Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28:276–331 Article Google Scholar
Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127–2132 ArticlePubMedPubMed Central Google Scholar
Oh H, Jun DW, Lee IH, Ahn HJ, Kim BO, Jung S, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:371–381 ArticlePubMed Google Scholar
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599 ArticlePubMed Google Scholar
Lee BT, Chang M, Lim C, Bae HS, Fong TL. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. JGH Open. 2021;5:258–263 ArticlePubMed Google Scholar
Lagoutte-Renosi J, Flammang M, Chirouze C, Beck-Wirth G, Bozon F, Brunel AS, et al. Real-life impact on lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected patients. Curr HIV Res. 2021;19:84–89 ArticleCASPubMed Google Scholar
Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21:910 ArticleCASPubMedPubMed Central Google Scholar
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206 ArticlePubMed Google Scholar
Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis. Clin Mol Hepatol. 2022;28:254–264 ArticlePubMed Google Scholar
Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408–414 ArticlePubMed Google Scholar
Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, et al. Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterol J. 2018;6:558–566 ArticlePubMedPubMed Central Google Scholar
Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Jeong SM, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel). 2021;13:1599 ArticleCASPubMed Google Scholar
Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016;95: e5146 ArticleCASPubMed Google Scholar
Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34:2259–2268 ArticlePubMed Google Scholar
Cid-Silva P, Fernandez-Bargiela N, Margusino-Framinan L, Balboa-Barreiro V, Mena-De-Cea A, Lopez-Calvo S, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124:479–490 ArticleCASPubMed Google Scholar
Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9:ofab621 ArticlePubMed Google Scholar
Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE. 2022;17: e0261760 ArticleCASPubMedPubMed Central Google Scholar
Brunet L, Mallon P, Fusco JS, Wohlfeiler MB, Prajapati G, Beyer A, et al. Switch from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: lipid changes and statin underutilization. Clin Drug Investig. 2021;41:955–965 ArticleCASPubMedPubMed Central Google Scholar
Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antivir Ther. 2022;27:13596535221082400 ArticleCAS Google Scholar
Lin HY, Tseng TC. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: facts and puzzles. Clin Mol Hepatol. 2022;28:181–182 ArticlePubMedPubMed Central Google Scholar
Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599–604 ArticleCASPubMed Google Scholar
Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24: e25702 ArticleCASPubMedPubMed Central Google Scholar
Kuo PH, Sun HY, Chuang YC, Wu PY, Liu WC, Hung CC. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis. 2020;92:71–77 ArticleCASPubMed Google Scholar
Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441–453 ArticlePubMed Google Scholar
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52 ArticleCASPubMed Google Scholar
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168–180 ArticleCASPubMed Google Scholar
Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:re3 ArticlePubMedPubMed Central Google Scholar
Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863–2871 ArticleCASPubMed Google Scholar
Luangrath V, Brodeur MR, Rhainds D, Brissette L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler Thromb Vasc Biol. 2008;28:1290–1295 ArticleCASPubMed Google Scholar
Brundert M, Heeren J, Merkel M, Carambia A, Herkel J, Groitl P, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011;52:745–758 ArticleCASPubMedPubMed Central Google Scholar
Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, et al. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34:1161–1170 ArticleCASPubMed Google Scholar
Wang Y, Xiong J, Niu M, Chen X, Gao L, Wu Q, et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2017;8:59666–59676 ArticlePubMedPubMed Central Google Scholar
Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 2020;71:2023–2032 ArticleCASPubMed Google Scholar
Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020;20:98 ArticleCASPubMedPubMed Central Google Scholar
Gilbert JM, Vest K, Kish TD. Long-term evaluation of changes in kidney function after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients living with HIV. Pharmacy (Basel). 2022;10:164 ArticlePubMed Google Scholar
van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta. 2009;1792:470–481 ArticlePubMed Google Scholar
Halpern A, Mancini MC, Magalhaes ME, Fisberg M, Radominski R, Bertolami MC, et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetol Metab Syndr. 2010;2:55 ArticlePubMedPubMed Central Google Scholar
Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–195 ArticlePubMed Google Scholar
Lim J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B. Liver Int. 2022;42:1517–1527 ArticleCASPubMed Google Scholar
Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21:567 ArticleCASPubMedPubMed Central Google Scholar
Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, et al. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res. 2022;52:153–164 ArticleCASPubMed Google Scholar
Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, et al. Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic hepatitis B initially treated with tenofovir disoproxil. Retrosp Obs Surv. 2021;21: e118721 Google Scholar
Karasahin O, Kalkan IA, Dal T, Toplu SA, Harputoğlu M, Mete AO, et al. Real-life data for tenofovir alafenamide fumarate treatment of hepatitis B: the pythagoras cohort. Hepat Mon. 2021;21:1–9 Google Scholar
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56:713–722 ArticleCASPubMedPubMed Central Google Scholar
Jeong S, Shin HP, Kim HI. Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B. Intervirology. 2022;65:94–103 ArticleCASPubMed Google Scholar
Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, et al. Tenofovir alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20:427-437.e425 ArticleCASPubMed Google Scholar
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–681 ArticleCASPubMed Google Scholar